AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01322256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET / CT
Description: PET / CT of the affected area
Study NCT01322256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone biopsy
Description: A bone biopsy is performed during pre-inclusion work up.
Study NCT01322256 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bloodwork
Description: CRP and procalcitonin are measured in the pre-inclusion work up.
Study NCT00149786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Therapy
Description: Family therapy will be given for a total of 24 hours over the course of 12 months.
Study NCT00149786 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ego-Oriented Individual Psychotherapy
Description: Individual therapy will be given for a total of 24 hours over the course of 12 months.
Study NCT03756116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epinephrine sprayed on the papilla
Description: Patients received sublingual Nitroglycerin will receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla before the withdrawal of endoscope.
Study NCT03756116 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saline sprayed on the papilla
Description: Patients received sublingual Nitroglycerin will receive 20 ml of normal saline sprayed on the duodenal papilla before the withdrawal of endoscope.
Study NCT02971709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shade Sail
Description: Shade sails had powder-coated or gout galvanized steel poles and a lighter colored shade cloth to transmit visual light. The shade cloth met Ultraviolet Protection Factor (UPF) ratings to reduce UV under the shade cloth by 94%. The final shade sail designs and sizes were determined with input from parks department staff and complied with all local engineering, building, and planning codes. Shade sails exceeded the minimum safety requirements for strength (for wind and snow load), resistance to light degradation, and UV transmission. The design minimized climbing access points and hazards to adjacent activities.
Study NCT02492243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCI
Study NCT02492243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ILR implantation
Study NCT02644837 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of device related trauma
Description: Observation and assessment of any trauma caused by the insertion of the first device used
Study NCT03342456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Hyclate Enteric-Coated Capsules
Description: group 1,0.1g\*10 capsules/box, produced by Yung Shin Pharm.Ind.(Kunshan) Co.,Ltd.
Study NCT03342456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin Capsules
Description: group 2,0.5g\*24 capsules/box, produced by United Laboratories（Zhuhai）
Study NCT03342456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole Enteric-Coated Tablets
Description: group 1 and group 2,5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc
Study NCT03342456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ilaprazole Enteric-Coated Tablets
Description: group 1 and group 2,5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc
Study NCT03342456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furazolidone Tablets
Description: group 1 and group 2,0.1g\*100 tablets/bottle,produced by Shanxi Yunpeng Pharmaceutical co.,Ltd.
Study NCT01369043 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E and Vitamin C
Description: Vitamin E 400 iu/dose daily times 56 days Vitamin C 500 mg/dose twice daily times 56 days
Study NCT03584906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DGG Harvesting approach
Description: An epithelialized graft is harvested from the superficial palate and then extraorally de-epithelialized in order to obtain a connective tissue graft
Study NCT02920385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Oral administration once daily alone or together with levothyroxine or Placebo
Study NCT03584906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ET harvesting approach
Description: A connective tissue graft is harvested from the palate after reflecting a primary palatal flap
Study NCT03342456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furazolidone Tablets
Description: group 1 and group 2,0.1g\*100 tablets/bottle,produced by Shanxi Yunpeng Pharmaceutical co.,Ltd.
Study NCT03342456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Citrate Tablets
Description: group 1 and group 2,110mg\*40 tablets/bottle,produced by Livzon Pharmaceutical Group Inc
Study NCT03342456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Citrate Tablets
Description: group 1 and group 2,110mg\*40 tablets/bottle,produced by Livzon Pharmaceutical Group Inc
Study NCT02920385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNAC
Description: Oral administration once daily alone or together with levothyroxine or semaglutide
Study NCT02920385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Oral administration alone or together with SNAC or oral semaglutide
Study NCT02920385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration once daily together with semaglutide
Study NCT03834441 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Oral HRSN screening
Description: Verbal screening delivered by an RA
Study NCT03584906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TDT harvesting approach
Description: A connective tissue graft is harvested from the palate after reflecting a primary palatal flap
Study NCT03584906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MT harvesting approach
Description: An epithelialized graft is harvested from the maxillary tuberosity and then extraorally de-epithelialized in order to obtain a connective tissue graft
Study NCT03584906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root coverage procedure
Description: A single or multiple gingival recession is treated with a coronally advanced flap and a connective tissue graft
Study NCT03834441 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Written HRSN screening
Description: Patient completes written screen on iPad.
Study NCT02256631 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: Administered by subcutaneous injection in the thigh
Study NCT02256631 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01LS
Description: Administered by subcutaneous injection in the thigh
Study NCT02869321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Study NCT02869321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine Sulfate
Study NCT02869321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl placebo
Study NCT02256631 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: Administered by subcutaneous injection in the thigh
Study NCT00957580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Pimasertib will be administered orally at a dose of 8 mg twice daily (BID) on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 60 mg BID, and 75 mg BID) until Maximum Tolerated Dose (MTD) is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
Study NCT00957580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Pimasertib will be administered orally at a dose of 8 mg BID on Days 1 to 21 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 45 mg BID, 60 mg BID, 75 mg BID, and 90 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
Study NCT00957580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Pimasertib will be administered orally at a dose of 60 mg BID on Days 1-28 of a 28-day cycle. The dose escalation will proceed to 75 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
Study NCT00957580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Pimasertib will be administered orally twice daily on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
Study NCT00957580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Pimasertib will be administered orally twice daily on Days 1 to 21 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
Study NCT03711461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endotracheal tube (double lumen)
Description: patients routinely use double lumen endotracheal intubation while they have received thoracoscopy
Study NCT03711461 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nonintubated
Description: patients receiving nonintubated anesthetic plan while they have received thoracoscopy
Study NCT04173585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib is a small molecule dipeptide binding the catalytic site of the 26 S proteasome. It acts as a potent, reversible, and specific inhibitor of proteasomes and thus impairs the degradation of ubiquitinated proteins. It has demonstrated anti-neoplastic activity in myeloma and lymphoma. It is approved and widely used in multiple myeloma both for first line treatment and relapsed patients.
Study NCT04173585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Gemtuzumab Ozogamicin is a monoclonal antibody directed against the myeloid surface antigen CD33. The antibody is linked to calicheamicin which serves as cytotoxic agent. For years, gemtuzumab ozogamicin has been tested in clinical AML trials. Though withdrawn from the US market in 2010, FDA approval was granted in September 2018, EU approval in April 2018 based on encouraging results from recent clinical trials using enhanced dosing schedules.
Study NCT02869321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate placebo
Study NCT02869321 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrostomy
Study NCT02869321 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Gastrostomy
Study NCT04346511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patients will have six, 0.25\*40mm sterilized stainless steel acupuncture needles (Dongbang Acupuncture, Inc., Seoul, South Korea) inserted into six acupoints (sites ST36, LV3, KI2, bilaterally) on their lower legs. After insertion, the needles will be stimulated at 2-4Hz, 10s at each point (1min total), immediately after insertion, 5min, 10min, 15min and just before removal.
Study NCT04346511 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: Patients will have six, 0.25\*40mm sterilized stainless steel acupuncture needles (Dongbang Acupuncture, Inc., Seoul, South Korea) inserted into six acupoints (sites ST36, LV3, KI2, bilaterally) on their lower legs. After insertion, the needles will be stimulated at 2-4Hz, 10s at each point (1min total), immediately after insertion, 5min, 10min, 15min and just before removal.
Study NCT01470222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Description: Menu-based recommendations to consume a high fiber, low glycemic load diet with education on nutrition and behavior change.
Study NCT01506024 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty direct lateral approach
Study NCT01506024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty posterior approach
Study NCT01506024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty, anterior approach
Study NCT03637283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anti-VEGF
Description: vitreoretinal surgery combined with intraoperative anti-VEGF
Study NCT03637283 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fan-shaped photocoagulation
Description: vitreoretinal surgery combined with intraoperative fan-shaped photocoagulation
Study NCT01963988 — intervention group
Intervention type: PROCEDURE
Intervention: Transurethral Coagulation (TUC)
Study NCT01963988 — intervention group
Intervention type: PROCEDURE
Intervention: Transurethral Resection(TUR)
Study NCT03320187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroderm TTS
Description: Transdermal nitroglycerin 5mg skin patch
Study NCT03320187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Description: Dinoprostone 3gm vaginal tablet will be used as the study method of labor induction
Study NCT03320187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dinoprostone
Description: Dinoprostone 3gm vaginal tablet will be used as the study method of labor induction
Study NCT01135992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Individually adjusted insulin degludec administered three times weekly with continued unchanged pre-trial OAD (oral anti-diabetic drug) treatment for 12 weeks
Study NCT01135992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Subjects continue their pre-trial insulin glargine once daily plus OAD (oral anti-diabetic drug) treatment for four weeks before switch to insulin degludec
Study NCT02184598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: 12 weeks of cognitive training; 4 sessions/week; duration 30 min
Study NCT02184598 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cognitive training
Description: In the control group, we will use a placebo training that will consist of the same exposure time of the active training but not related to any element of cognitive training. To this end, we will set up an online platform with quiz and educational videos - being the most related to school content - without any component of executive function or working memory.
Study NCT03245346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEA
Description: Thoracic epidural catheterization will be performed and epidural anesthesia will be maintained with 0.25% ropivacaine during surgery. General anesthesia will be maintained with inhalation (sevoflurane) and muscle relaxants will be administered when considered necessary.
Study NCT03245346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCEA
Description: Patient-controlled epidural analgesia (0.15% ropivacaine infusion) will be provided after surgery.
Study NCT03245346 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GA
Description: General anesthesia will be maintained with inhalation (sevoflurane) and sufentanil infusion, and muscle relaxants will be administered when considered necessary.
Study NCT03245346 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PCIA
Description: Patient-controlled intravenous analgesia (1ug/ml sufentanil) will be provided after surgery.
Study NCT02852967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil
Study NCT02852967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets matching belumosudil
Study NCT02852967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching belumosudil
Study NCT02903823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen bolus injection
Description: A baclofen bolus injection (50 micrograms) will be administered daily after the patient returns from radiology to position catheter injection location. The injection may be given at C4, T4, T10 or L2 spinal locations depending on the catheter tip location.
Study NCT01129492 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-level Laser therapy
Description: A continuous wave (CW) diode laser device (830nm, infrared) with a beam area of 0.2827cm2 and using the punctual method, continuous emission mode, output power of de 50mW and fluence of 70J/cm2 (40 seconds at the point of application).
Study NCT01129492 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low-level Laser therapy
Description: A continuous wave (CW) diode laser device (830nm, infrared) with a beam area of 0.2827cm2 and using the punctual method, continuous emission mode, output power of de 50mW and fluence of 70J/cm2 (40 seconds at the point of application).
Study NCT00106041 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Veterans Integrated Palliative Care Nurse Case Manager
Description: Palliative Care nurse case management
Study NCT02690766 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Behavioral Weight Change Intervention
Description: Participants enrolled in Phase 2 of the study will meet once a month for 75 minutes over the course of 4 months. Within this 75 minutes, they will complete 25 minutes of physical activity with a licensed physical activity instructor that is very experienced with working with this population, review and discuss various topics/lessons that relate to diabetes, nutrition, survivorship and physical activity with the study's interventionist and Group Leader
Study NCT02501837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon-Spray
Description: Intranasal administration of 24 IU Oxytocin
Study NCT02501837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Syntocinon-Spray
Description: Intranasal administration of 24 IU Oxytocin
Study NCT04320290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Direct Acting Antivirals
Description: 8 weeks of DAA treatment
Study NCT02960633 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Corail with collar.
Study NCT02399722 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WICVAC
Description: combined wound therapy
Study NCT02960633 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Corail without collar.
Study NCT02399722 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VAC mono therapy
Description: mono therapy
Study NCT01245621 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Later entry group
Description: 1. Advanced Practice Palliative Care Nurse Interventionist instituting a phone-based: a) Charting Your Course (CYC)-Patient Curriculum (6-session manualized); b) Creativity Optimism Planning Expert Information (COPE) Caregiver Curriculum (3 session manualized) and c) ongoing contact as determined by the Palliative Care Team assessment/plan; and~2. Comprehensive Palliative Care Team Assessment \& Management Plan.
Study NCT03549286 — intervention group
Intervention type: OTHER
Intervention: Questionnaire passation
Description: Questionnaires assessing general knowledge about Down's syndrome screening, specific knowledge of NIPT for Down's syndrome and patient's satisfaction about provided information.
Study NCT04602143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Description: Apply 12.5mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 4 or 6 weeks until next IVF treatment.
Study NCT05399927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Intervention
Description: The objective of this study is to observe the effects that music produces on physiological parameters, in patients with Acute Cardiovascular Disease (ACVD), and to determine its influence on the types or doses of drugs administered during initial care. The intervention study is carried out in the ambulance cabin during the time of transfer to the destination Hospital.
Study NCT00066612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Irinotecan will be given 250 mg/m\^2 through intravenous (IV) for 90 minutes on day 1 for every 21 days until tumor progression or unacceptable toxicity or other reason for discontinuation occurs
Study NCT02499627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Brentuximab will be given intravenously at a total dose of 1.8 mg/kg on day 1 of each 21 days-based cycle, for 6 cycles.
Study NCT02499627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered at a dose of 90 mg/m2 on day 1 and 2 of each 21 days-based cycle, for 6 cycles.
Study NCT03712774 — intervention group
Intervention type: OTHER
Intervention: EORTC QLQ C30
Description: standardized questionaire